# AstraZeneca Phase III Failure of Wainua (Eplontersen) in ATTR Cardiomyopathy Sends Shares Down

> clinical trial · REPORTED · 2026-07-09

AstraZeneca's gene-silencing drug Wainua (eplontersen) unexpectedly failed its Phase III trial in transthyretin-mediated amyloid cardiomyopathy on July 9, 2026, sending AZN shares down $10.88 to close at $178.40. The setback is a significant clinical reversal for AstraZeneca's cardiology pipeline.

About AstraZeneca: AstraZeneca is a global biopharmaceutical company focused on oncology, cardiovascular, renal, metabolic, respiratory, and rare diseases, developing both small-molecule drugs and biologics.

- Company: AstraZeneca
- Sector: therapeutics
- Primary source: https://www.bioworld.com/topics/85-bioworld-medtech

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.